STOCK TITAN

International Stem Cell delays Q3 report after sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

International Stem Cell Corporation (ISCO) expects to file its Form 10-Q on or before the fifth calendar day following the prescribed due date. The delay follows the third-quarter 2026 closing of the disposition of its Lifeline Cell Technology business. ISCO says discontinued-operations accounting requires separating current-period results, retrospectively recasting prior comparative statements, determining the gain or loss on disposition, and allocating income taxes between continuing and discontinued operations. The company does not anticipate a significant change in results of operations from the corresponding period last year.

Quarter ended September 30, 2026 Reporting period for the Form 10-Q
Expected filing deadline On or before the fifth calendar day following the prescribed due date Form 10-Q filing extension expectation
discontinued operation financial
"present the results of the LCT Business as a discontinued operation"
A discontinued operation is a part of a company that has been sold, closed, or is planned to be shut down, and will no longer be part of its ongoing business activities. For investors, it matters because it can significantly affect a company's financial results and future outlook, similar to removing a large, ongoing project from a company's operations. Recognizing discontinued operations helps investors better understand a company's current performance separate from parts that are no longer active.
retrospective recasting financial
"retrospective recasting of all prior period comparative financial statements"
continuing operations financial
"separation of the LCT Business’s results from continuing operations"
Continuing operations are the parts of a company's business that it expects to keep running into the future, excluding divisions or activities it has sold, closed, or classified as discontinued. Investors watch continuing operations because they show the company’s core ability to generate revenue and profit over time — like evaluating the healthy, ongoing crops on a farm rather than one-off harvests from fields you've already sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does ISCO expect to file its delayed 10-Q?

ISCO expects to file its Form 10-Q on or before the fifth calendar day following the prescribed due date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

     
(Check One):   ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR
   
    For Period Ended:  September 30, 2026
   
    ¨ Transition Report on Form 10-K
    ¨ Transition Report on Form 20-F
    ¨ Transition Report on Form 11-K
    ¨ Transition Report on Form 10-Q
   
    For the Transition Period Ended:

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

PART I-REGISTRANT INFORMATION

 

International Stem Cell Corporation

Full name of Registrant

 

N/A

Former name if Applicable

 

9745 Businesspark Ave

Address of Principal Executive Office (Street and number)

 

San Diego, California 92131

City, State and Zip Code

 

 

 

 

   

 

 

PART II-RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

x   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

International Stem Cell Corporation (the "Company") is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from the disposition of the Company’s Lifeline Cell Technology business (the “LCT Business”), the closing of which occurred during the third quarter of 2026. In accordance with Accounting Standards Codification 205-20, Discontinued Operations, the Company is required to present the results of the LCT Business as a discontinued operation in its condensed consolidated financial statements for the three months ended September 30, 2026.  The accounting treatment requires, among other things, the separation of the LCT Business’s results from continuing operations for the current period, the retrospective recasting of all prior period comparative financial statements to present the LCT Business as a discontinued operation, the determination of the gain or loss on disposition, and income taxes between continuing and discontinued operations. The complexity of this discontinued operations accounting, combined with the need to ensure the accuracy and completeness of the retrospective recasting of prior periods, has required additional time to complete the Company’s financial close process for the quarter ended September 30, 2026. The Company has been working diligently to complete the discontinued operations presentation and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification
           
  Russell Kern     (760)     940-6383
  (Name)     (Area Code)     (Telephone Number)
   
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No
   
   
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 2 

 

 

International Stem Cell Corporation

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 17, 2026 By: /s/ Russell Kern
      Russell Kern
      Executive Vice President and Chief Scientific Officer
(Principal Financial Officer)

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Keep reading